ARRY vs ITRN

ARRY's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates poor financial health, with weak profitability, declining revenue, and high leverage. The absence of an Altman Z-Score raises concern, as the Debt/Equity ratio of 2.94 and negative ROE (-19.02%) suggest elevated bankruptcy risk. Despite a modest Price/Sales of 0.82 and a forward P/E of 7.86, the company's -17.9% YoY revenue decline and negative profit margins undermine valuation appeal. Analysts recommend 'buy' with a $10.07 target, but this optimism appears disconnected from deteriorating fundamentals. The 52-week price range ($3.76–$12.23) and recent 1M drop of 37.6% reflect high volatility and weak market confidence.

ITRN exhibits exceptional financial health with a Piotroski F-Score of 8/9, indicating strong operational efficiency and balance sheet strength. While the current price of $53.54 is a significant premium over the Graham Number ($26.84), it remains well below the growth-based intrinsic value of $67.31. The company combines steady double-digit growth with a highly attractive 11.21% dividend yield and negligible debt (D/E 0.02). Despite a bearish technical trend score and weak insider sentiment, the fundamental data suggests a high-quality compounder with significant margin of safety in its health metrics.